GW296115
GW296115 is a multi-target inhibitor with the following IC50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3. GW296115 downregulates the phosphorylation of S317 site on ULK1 and S351 site on P62, which are AMPK substrates driven by BRSK2. GW296115 does not alter the phosphorylation level of AMPK at T172, reduces nutrient deprivation-mediated Autophagy and autophagosome formation, and enhances Apoptosis. GW296115 exhibits anticancer activity against triple-negative breast cancer. GW296115 is applicable for breast cancer-related research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 118458-58-5
- Fòrmula: C22H15N3O4
- Peso molecular:385.37
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
PDGFRβ 1.8 μM (IC50) |
ULK1 |
DRAK1 28 nM (IC50) |
DRAK2 5.5 nM (IC50) |
GW296115 (1 μM) inhibits 25 out of 403 wild-type human kinases by over 90% at a concentration of 1 μM, with a selectivity index of 0.062[1].
GW296115 potently inhibits 6 IDG dark kinases in enzymatic assays, with IC50 values ranging from 5.5 nM (DRAK2) to 89 nM (DCAMKL3)[1].
GW296115 (1 μM; 72 h) exerts no effect on cell proliferation in 17 tested cancer cell lines and normal cell lines (including non-malignant MCF10A and MRC-5) following treatment at 1 μM for 72 h[1].
GW296115 (incubated for 2 h) potently binds to BRSK2 in living HEK293 cells with an IC50 of 107 nM, confirming that it is a cell-active BRSK2 inhibitor[1].
GW296115 (2.5 μM; 2-6 h) abolishes BRSK2-induced phosphorylation of AMPK substrates in HEK293T cells (this effect is observed at both 2 h and 6 h) and induces hyperphosphorylation of BRSK2 at the T174 site[1].
GW296115 (2-5 μM) inhibits autophagy and enhances apoptosis in MDA-MB-231 triple-negative breast cancer cells, while it also inhibits autophagy and enhances apoptosis in BT-474 estrogen receptor-positive breast cancer cells[2].
GW296115 (2 μM; 24 h) inhibits the growth of MDA-MB-231 triple-negative breast cancer cells[2].
GW296115 (2-3 μM; 72 h) reduces the 3D invasiveness of MDA-MB-231 triple-negative breast cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:17 cancer and normal cell lines (including SUM159, MCF7, MCF10A, HCC1954, COV362, Kuramochi, PC-3, DU145, H729, HCT116, A549, MRC-5, Colo829, A375, Cas1, HPAF-II, Panc-1)
-
Concentration:1 μM
-
Incubation Time:72 h
-
Result:Did not impact cell growth in any of the tested cell lines, and is considered generally non-toxic to cells.
-
Cell Line:HEK293T cells transiently expressing hcRED, wild-type BRSK2, or kinase-dead BRSK2 (K48A, T174A)
-
Concentration:2.5 μM
-
Incubation Time:2 h, 6 h
-
Result:Ablated wild-type BRSK2-induced AMPK substrate phosphorylation at both 2-h and 6-h time points.
Left phosphorylation of AMPK at T172 unaltered, but hyper-induced phosphorylation of BRSK2 at T174 in all samples except those expressing BRSK2 T174A.
-
Cell Line:MDA-MB-231
-
Concentration:2-3 μM
-
Incubation Time:72 h
-
Result:Reduced 3D Matrigel tumor cell invasiveness (invadopodia per spheroid) by over 75% compared to vehicle control.
Chemical Information
-
No. CAS 118458-58-5
-
Peso molecular 385.37
-
Fòrmula C22H15N3O4
-
SMILES
O=C1NC(C2=C3C4=C(C=CC(OC)=C4)NC3=C5NC6=CC=C(OC)C=C6C5=C21)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Tamir TY, et al. PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor. Sci Rep. 2020 Sep 28;10(1):15826. [Content Brief]
[2]. Maiti A, et al. BRSK2 plays a role in autophagy and cancer cell growth and survival under nutrient deprivation stress via the PIK3C3 pathway. Sci Rep. 2025 Nov 19;15(1):40651. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GW296115 Related Classifications
HY-186224 Related Classifications
Powered by Bioz